Clinical Trial Update: Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and immunogenicity of a Personalized Genomic Vaccine in combination with Tumor Treating Fields for glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Personalized Genomic Vaccine

Snippet

Sponsor: Adilia Hormigo | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING